Cargando…

CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies

SIMPLE SUMMARY: CD123 is overexpressed in multiple hematologic malignancies. Advances in CD123-targeted therapies over the past decade have positioned this molecule as an integral biomarker in current practice. This review provides an overview of CD123 biology and in-depth discussion of clinical lab...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Achi, Hanadi, Dupont, Edouard, Paul, Shilpa, Khoury, Joseph D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690688/ https://www.ncbi.nlm.nih.gov/pubmed/33113953 http://dx.doi.org/10.3390/cancers12113087

Ejemplares similares

Gut and liver involvement in pediatric hematolymphoid malignancies
por: Devarapalli, Umeshreddy V, et al.
Publicado: (2022)

Hematolymphoid neoplasms in effusion cytology
por: Monappa, Vidya, et al.
Publicado: (2018)

Serous fluids and hematolymphoid disorders
por: Gabali, Ali
Publicado: (2022)

Cell-blocks and hematolymphoid lesions
por: Alrajjal, Ahmed, et al.
Publicado: (2021)

Histiocytic sarcoma of the lymph node: a rare and aggressive hematolymphoid malignancy
por: Deepa, Goel, et al.
Publicado: (2020)

Artificial Intelligence and Digital Microscopy Applications in Diagnostic Hematopathology
por: El Achi, Hanadi, et al.
Publicado: (2020)

Epidemiology, Clinical Characteristics, and Prognostic Factors in Critically Ill Patients with Hematolymphoid Malignancy
por: Siddiqui, Suhail S, et al.
Publicado: (2021)

Mucocutaneous Findings in Hematolymphoid Neoplasms: An Observational Study
por: Batra, Anmol, et al.
Publicado: (2023)

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
por: Testa, Ugo, et al.
Publicado: (2014)

Correction to: Automated classification of cytogenetic abnormalities in hematolymphoid neoplasms
Publicado: (2022)

Effect of dose rate on pulmonary toxicity in patients with hematolymphoid malignancies undergoing total body irradiation
por: Kim, Dong-Yun, et al.
Publicado: (2018)

Preliminary Cytomorphologic Diagnosis of Hematolymphoid Malignancies in Effusions: A Cyto-histo Correlation with Lessons on Restraint
por: Patel, Bidish K., et al.
Publicado: (2022)

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
por: Testa, Ugo, et al.
Publicado: (2019)

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
por: El Achi, Hanadi, et al.
Publicado: (2021)

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia
por: Angelova, Evgeniya, et al.
Publicado: (2019)

Spectrum of renal involvement in hematolymphoid neoplasms: Renal biopsy findings of 12 cases
por: Vankalakunti, M., et al.
Publicado: (2015)

Fine needle aspiration of hematolymphoid lesions of the thyroid: Onsite adequacy and ancillary testing
por: Abada, Evi, et al.
Publicado: (2022)

Hematolymphoid tumor of prostate: Diffuse large B cell lymphoma case report
por: Ochirjav, Enkhee, et al.
Publicado: (2023)

Development Of [(211)At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies
por: Laszlo, George S., et al.
Publicado: (2022)

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
por: Rakheja, Dinesh, et al.
Publicado: (2013)

Report of two cases of myxoinflammatory fibroblastic sarcomas with preceding hematolymphoid neoplasms: Is there any association?
por: Aminparast, Zahra, et al.
Publicado: (2022)

Identification of a 107-kD glycoprotein that mediates adhesion between stromal cells and hematolymphoid cells
Publicado: (1991)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
por: Cai, Tianyu, et al.
Publicado: (2022)

A Rare Extramedullary and Extralymphoid Presentation of Mixed Phenotypic Blastic Hematolymphoid Neoplasm: A Study of Two Cases
por: Ghodke, Kiran, et al.
Publicado: (2017)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Characterization of D-Cyclin Proteins in Hematolymphoid Neoplasms: Lack of Specificity of Cyclins D2 and D3 Expression in Lymphoma Subtypes
por: Metcalf, Ryan A, et al.
Publicado: (2010)

Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma
por: Skala, Stephanie L, et al.
Publicado: (2019)

Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens
por: Su, Hsuan, et al.
Publicado: (2022)

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission
por: Xie, L H, et al.
Publicado: (2017)

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy
por: Wu, Haibin, et al.
Publicado: (2021)

Diagnostic Challenges of CD4(+)/CD56(+)/CD123(+) hematological neoplasms
por: Thiago, Leandro S., et al.
Publicado: (2013)

Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients
por: Aref, Salah, et al.
Publicado: (2020)

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
por: Mani, Rajeswaran, et al.
Publicado: (2018)

CD123-Targeted Nano-Curcumin Molecule Enhances Cytotoxic Efficacy in Leukemic Stem Cells
por: Nirachonkul, Wariya, et al.
Publicado: (2021)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2022)

CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Bôle-Richard, Elodie, et al.
Publicado: (2022)

CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
por: Pelosi, Elvira, et al.
Publicado: (2023)

Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
por: Marone, Romina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1n57ijqrgcs2qgivfn4uqftl51